Cargando…

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is markedly higher in younger and never-smoker p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marinelli, Daniele, Siringo, Marco, Metro, Giulio, Ricciuti, Biagio, Gelibter, Alain J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576009/ https://www.ncbi.nlm.nih.gov/pubmed/36303600 http://dx.doi.org/10.7573/dic.2022-3-1

Ejemplares similares

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022)

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
por: Siringo, Marco, et al.
Publicado: (2023)

Non-small-cell lung cancer: how to manage RET-positive disease
por: Andrini, Elisa, et al.
Publicado: (2022)

Advanced non-small-cell lung cancer: how to manage non-oncogene disease
por: De Giglio, Andrea, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
por: Pecci, Federica, et al.
Publicado: (2022)

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
por: De Giglio, Andrea, et al.
Publicado: (2023)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
por: Guerreiro Stucklin, Ana S., et al.
Publicado: (2019)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
por: Dai, Yinghuan, et al.
Publicado: (2022)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2022)

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
por: Britschgi, Christian, et al.
Publicado: (2020)

Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
por: Xiao, Zhiwei, et al.
Publicado: (2020)

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer
por: Vaishnavi, A., et al.
Publicado: (2013)

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017)

Non-coding RNAs in lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2014)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
por: Farago, Anna F., et al.
Publicado: (2015)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

ALK, ROS1, RET and NTRK1–3 Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers
por: Mulkidjan, Rimma S., et al.
Publicado: (2023)

EGFR mutations and ROS1 and ALK rearrangements in a large series of non‐small cell lung cancer in South India
por: Tarigopula, Anil, et al.
Publicado: (2020)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
por: Desai, Ami V, et al.
Publicado: (2022)

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial
por: Shaw, Alice T., et al.
Publicado: (2017)

Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
por: Yao, Yi, et al.
Publicado: (2018)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
por: Ricciuti, Biagio, et al.
Publicado: (2017)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
por: De Giglio, Andrea, et al.
Publicado: (2022)

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
por: Chang, Xing, et al.
Publicado: (2019)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0f6tptv8b0uphe3km3l6j5f21o